Tissue repair
Protein therapeutics designed around cell-membrane repair and protection from acute and chronic tissue injury.
Technology
Protein and peptide platforms built around repair, resilience and disease biology
The legacy TRIM-edicine portfolio combines protein therapeutics, aging and cellular-homeostasis biology, and bioactive peptide programs, with MG53, MG29 and ATAP as the three central technology areas.
Platform overview
Three complementary approaches
The portfolio spans membrane repair and tissue protection, cellular homeostasis and aging biology, and peptide-based anticancer therapeutics.
Aging & cellular homeostasis
Biology focused on cellular homeostasis, age-related dysfunction, and the loss of normal cellular repair capacity.
Oncology peptides
Bioactive peptide therapeutics developed around apoptosis-related mechanisms for cancer.
Membrane repair biology
Cell membrane repair and tissue protection
The company's historical research describes MG53 as an essential molecular component of the intrinsic cell membrane repair machinery. Membrane damage creates a local oxidative environment that promotes MG53 oligomerization and recruitment of intracellular vesicles to the injury site, helping restore membrane integrity.
TRIM-edicine has investigated recombinant MG53 protein and approaches that modulate endogenous MG53. Archived research and company materials report studies in muscle, kidney, lung, heart, cornea, skin and other tissue-injury settings, with the broader goal of limiting acute damage and chronic inflammation.
Selected publications highlighted by the legacy site
- 2022Membrane-delimited signaling and cytosolic action of MG53 preserve hepatocyte integrity during drug-induced liver injury, Journal of Hepatology
- 2021MG53 suppresses NF-κB activation to mitigate age-related heart failure, JCI Insight
- 2021MG53 Preserves Neuromuscular Junction Integrity and Alleviates ALS Disease Progression, Antioxidants
- 2021Recombinant MG53 Protein Protects Mice from Lethal Influenza Virus Infection, American Journal of Respiratory and Critical Care Medicine
- 2021Muscle multiorgan crosstalk with MG53 as a myokine for tissue repair and regeneration, Current Opinion in Pharmacology
- 2021MG53, A Tissue Repair Protein with Broad Applications in Regenerative Medicine, Cells
- 2015MG53-mediated cell membrane repair protects against acute kidney injury, Science Translational Medicine
- 2014Treatment of acute lung injury by targeting MG53-mediated cell membrane repair, Nature Communications
- 2012Recombinant MG53 Protein Modulates Therapeutic Cell Membrane Repair in Treatment of Muscular Dystrophy, Science Translational Medicine
- 2009MG53 nucleates assembly of cell membrane repair machinery, Nature Cell Biology
Cellular homeostasis
Cellular homeostasis and age-related dysfunction
MG29 is a skeletal-muscle-enriched member of the synaptophysin family. The archived site describes MG29 as a program directed toward age-related dysfunction, with emphasis on cellular homeostasis, plasticity and repair capacity.
The legacy Technology page highlights early mechanistic work published in Nature Cell Biology in 2002 and positions MG29 as a potential route to addressing biological changes associated with aging.
Selected publications highlighted by the legacy site
- 2002Dysfunction of store-operated calcium channel in muscle cells lacking mg29, Nature Cell Biology
- 2006Muscle aging is associated with compromised Ca2+ spark signaling and segregated intracellular Ca2+ release, Journal of Cell Biology
Peptide therapeutics
Apoptosis-related approaches for cancer
ATAP is the company's historical peptide-based anticancer platform. The archived site describes ATAP-derived molecules as designed to engage apoptosis-related mechanisms in cancer cells.
Company news reports that ATAP-M8 received authorization from China's Center for Drug Evaluation in March 2022 to enter human clinical testing in patients with advanced solid tumors.
Selected publications highlighted by the legacy site
- 2014Core-shell nanoparticle-based peptide therapeutics and combined hyperthermia for enhanced cancer cell apoptosis, ACS Nano
- 2014Amphipathic tail-anchoring peptide is a promising therapeutic agent for prostate cancer treatment, Oncotarget
- 2011Amphipathic tail-anchoring peptide and Bcl-2 homology domain-3 (BH3) peptides from Bcl-2 family proteins induce apoptosis through different mechanisms, Journal of Biological Chemistry
- 2007The tail-anchoring domain of Bfl1 and HCCS1 targets mitochondrial membrane permeability to induce apoptosis, Journal of Cell Science
The old website included future development timelines that are now outdated. Current ATAP-M8 and other pipeline stages should be verified before production launch.